---
document_datetime: 2026-01-27 15:58:13
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/cetrotide-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: cetrotide-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.3347603
conversion_datetime: 2026-02-01 20:41:28.478065
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.1
  docling: 2.71.0
  docling-core: 2.62.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Cetrotide

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 27/01/2026                          |                                             | Annex II                         |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000322807   | PRODUCTS - C.I.z Other variation - Accepted C.I.z - to update Annex II of the Product Information B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE to implement the recommendation of the CHMP Rapporteur team to align it with section 4.2 of the SmPC.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| Variation type IA / | This was an application for a group of variations. A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where | 27/11/2025 | N/A | EMA/VR/0000314540 |

<div style=\"page-break-after: always\"></div>

| Article 61(3) / EMA/N/0000308409      | - Notification acc. Article 61(3) - Accepted Update of the Labelling to align instruction for Use (IFU) concerning the injection angle and site. The update provides clearer guidance on the recommended injection site in the lower abdominal area and on maintaining an appropriate distance from the navel, as well as specifying a preferred injection angle to support correct subcutaneous administration. The MAH is also taking the opportunity to introduce some minor editorial changes to the labelling and package leaflet.                               | 24/11/2025   | Labelling and PL   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------------|
| Variation type IB / EMA/VR/0000307159 | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real | 10/11/2025   |                    |

<div style=\"page-break-after: always\"></div>

|                            | time data - Accepted   |             |
|----------------------------|------------------------|-------------|
| PSUR / EMA/PSUR/0000288224 | - -                    | Maintenance |